Skip to content
2000
Volume 29, Issue 14
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

The evolution in research and clinical settings of targeted therapies has been inspired by the progress of cancer chemotherapy to use small molecules and monoclonal antibodies for targeting specific disease-associated genes and proteins for noninfectious chronic diseases. In addition to conventional protein inhibition and activation strategies as drug discovery modalities, new methods of targeted protein degradation and regulation using molecular glues have become an attractive approach for drug discovery. Mechanistically, molecular glues trigger interactions between the proteins that originally did not interact by forming ternary complexes as protein-protein interaction (PPI) modulators. New molecular glues and their mechanisms of action have been actively investigated in the past decades. An immunomodulatory imide drug, thalidomide, and its derivatives have been used in the clinic and are a class of molecular glue that induces degradation of several neo-substrates. In this review, we summarize the development of molecular glues and share our opinions on the identification of novel molecular glues in an attempt to promote the concept and inspire further investigations.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867328666210806113949
2022-04-01
2025-07-16
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867328666210806113949
Loading

  • Article Type:
    Review Article
Keyword(s): CR8; E7820; Molecular glue; protein degradation; protein-protein interaction; thalidomide
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test